Nicotine therapeutic benefits: Difference between revisions

Line 214:

<br>

==Alzheimer / Dementia / MCI==

='''Alzheimer / Dementia / Mild Cognitive Imparement (MCI)'''=

Line 225:

*Citation: Inestrosa, N.C., Godoy, J.A., Vargas, J.Y. et al. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation. Neuromol Med 15, 549–569 (2013). doi: 10.1007/s12017-013-8242-1

*Acknowledgements: We thank Dr. Rodrigo Varas for his help with the electrophysiological studies of the α7-nAChR. This work was supported by a grant from FONDECYT No 120156 to N.C.I; predoctoral fellowships from CONICYT to G.G.F., M.S.A. F.G.S., J.A.R. and from Fundación Gran Mariscal de Ayacucho to J.Y.V. The Basal Center of Excellence in Science and Technology CARE was funded by CONICYT/PFB 12/2007.

===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/ Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]===

Line 234:

Line 233:

*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/pdf/znl91.pdf PDF Version]

*Citation: Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050; PMCID: PMC3466669.

===2010 [https://www.tandfonline.com/doi/abs/10.1080/13607860220126808 Nicotine's effect on neural and cognitive functioning in an aging population]===

Line 245:

Line 243:

*[https://sci-hub.st/10.1080/13607860220126808 PDF Version]

*Citation: K. N. Murray & N. Abeles (2002) Nicotine's effect on neural and cognitive functioning in an aging population, Aging & Mental Health, 6:2, 129-138, DOI: 10.1080/13607860220126808

===2002 [https://pubmed.ncbi.nlm.nih.gov/12436427/ Nicotinic receptors in aging and dementia]===

Line 256:

Line 253:

*Citation: Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol. 2002 Dec;53(4):641-55. doi: 10.1002/neu.10102. PMID: 12436427.

*Keywords: nAChR; neuroprotection; Alzheimer’s disease; Parkinson’s disease; acetylcholine

===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===

*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer's disease, schizophrenia or ADHD as well as normal nonsmoking adults.

*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.

===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]===

Line 270:

Line 265:

*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]

*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.

===1992 [https://pubmed.ncbi.nlm.nih.gov/1410164/ Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease]===

Line 279:

Line 273:

*Citation: Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl). 1992;108(4):485-94. doi: 10.1007/BF02247426. PMID: 1410164.

*Acknowledgements. This research was supported by British-American Tobacco Co. Ltd. BJS thanks the Wellcome Trust and the Eleanor Peel Foundation for support.

===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]===

Line 288:

Line 281:

*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.

*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.

===1989 [https://pubmed.ncbi.nlm.nih.gov/2597885/ The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type]===

@@ Line 214: / Line 214: @@
 <br>
-==Alzheimer / Dementia / MCI== <!--T:35-->
+='''Alzheimer / Dementia / Mild Cognitive Imparement (MCI)'''= <!--T:35-->
@@ Line 225: / Line 225: @@
 *Citation: Inestrosa, N.C., Godoy, J.A., Vargas, J.Y. et al. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation. Neuromol Med 15, 549–569 (2013). doi: 10.1007/s12017-013-8242-1
 *Acknowledgements: We thank Dr. Rodrigo Varas for his help with the electrophysiological studies of the α7-nAChR. This work was supported by a grant from FONDECYT No 120156 to N.C.I; predoctoral fellowships from CONICYT to G.G.F., M.S.A. F.G.S., J.A.R. and from Fundación Gran Mariscal de Ayacucho to J.Y.V. The Basal Center of Excellence in Science and Technology CARE was funded by CONICYT/PFB 12/2007.
 ===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/ Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== <!--T:38-->
@@ Line 234: / Line 233: @@
 *[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/pdf/znl91.pdf PDF Version]
 *Citation: Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050; PMCID: PMC3466669.
 ===2010 [https://www.tandfonline.com/doi/abs/10.1080/13607860220126808 Nicotine's effect on neural and cognitive functioning in an aging population]=== <!--T:40-->
@@ Line 245: / Line 243: @@
 *[https://sci-hub.st/10.1080/13607860220126808 PDF Version]
 *Citation: K. N. Murray & N. Abeles (2002) Nicotine's effect on neural and cognitive functioning in an aging population, Aging & Mental Health, 6:2, 129-138, DOI: 10.1080/13607860220126808
 ===2002 [https://pubmed.ncbi.nlm.nih.gov/12436427/ Nicotinic receptors in aging and dementia]=== <!--T:42-->
@@ Line 256: / Line 253: @@
 *Citation: Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol. 2002 Dec;53(4):641-55. doi: 10.1002/neu.10102. PMID: 12436427.
 *Keywords: nAChR; neuroprotection; Alzheimer’s disease; Parkinson’s disease; acetylcholine
 ===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===
 *For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer's disease, schizophrenia or ADHD as well as normal nonsmoking adults.
 *Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.
 ===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== <!--T:44-->
@@ Line 270: / Line 265: @@
 *[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]
 *Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.
 ===1992 [https://pubmed.ncbi.nlm.nih.gov/1410164/ Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease]=== <!--T:46-->
@@ Line 279: / Line 273: @@
 *Citation: Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl). 1992;108(4):485-94. doi: 10.1007/BF02247426. PMID: 1410164.
 *Acknowledgements. This research was supported by British-American Tobacco Co. Ltd. BJS thanks the Wellcome Trust and the Eleanor Peel Foundation for support.
 ===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== <!--T:48-->
@@ Line 288: / Line 281: @@
 *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.
 *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.
 ===1989 [https://pubmed.ncbi.nlm.nih.gov/2597885/ The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type]=== <!--T:50-->